Imunon Inc
IMNN
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.18M
Close$
$3.66
149.9% upside
Current Fair Value
149.9% upsideUndervalued by 149.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.18 Million |
|---|---|
| Enterprise Value | $7.16 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.83 |
| Beta | 1.98 |
| Outstanding Shares | 5,232,625 |
Return
| Return on Equity | -82133.80% |
|---|---|
| Return on Assets | -22952.73% |
| Return on Invested Capital | -33695.78% |
Valuation & Multiples
| P/E Ratio | -0.32 |
|---|---|
| PEG | -12.09 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.1 |
| Debt to Equity | 1.87 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.87
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.61
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 6.09%▼ 3.92% |
|---|---|
| Total Invested | $753,828▼ 53.67% |
| Investors Holding | 23▲ 5.00% |
ESG Score
No data
About Imunon Inc
27 employees
CEO: Michael Tardugno Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid v...